Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
After being diagnosed with immune thrombocytopenia (ITP) in 2019, Jaimie's rare disease journey began. #ASH20 is an opportunity for us to continue innovating for patients like her. Read more: https://t.co/yvMZt4ecPK https://t.co/RvpkbDgttL
— UCB News (@ucb_news) 05.12.2020 -
We look forward to connecting with members of the hematology community at #ASH20 who share in our mission to advance ITP research. Hear from Maya Isaila, UCB Medical Lead, Hematology, on why medical meetings, even virtual, are more important than ever: ht
— UCB News (@ucb_news) 05.12.2020 -
We're joining the epilepsy community at #AES2020 and proud to showcase the latest research on our portfolio and pipeline. Registered delegates can visit our virtual booth to learn more about our efforts in #epilepsy. https://t.co/vW1cX4jYAE
— UCB News (@ucb_news) 05.12.2020
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
